دورية أكاديمية
أعرض في EDS

Enhanced Maturation of 3D Bioprinted Skeletal Muscle Tissue Constructs Encapsulating Soluble Factor-Releasing Microparticles.

التفاصيل البيبلوغرافية
العنوان: Enhanced Maturation of 3D Bioprinted Skeletal Muscle Tissue Constructs Encapsulating Soluble Factor-Releasing Microparticles.
المؤلفون: de Barros NR; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Darabi MA; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Ma X; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA., Diltemiz SE; Department of Chemistry, Eskisehir Technical University, Eskisehir, 26470, Turkey., Ermis M; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Hassani Najafabadi A; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Nadine S; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.; CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, Aveiro, 3810-193, Portugal., Banton EA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA., Mandal K; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Abbasgholizadeh R; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Falcone N; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Mano JF; CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, Aveiro, 3810-193, Portugal., Nasiri R; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Herculano RD; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Zhu Y; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Ostrovidov S; Department of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA., Lee J; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.; Department of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), Pohang, 790-784, Republic of Korea., Kim HJ; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.; College of Pharmacy, Korea University, Sejong, 30019, Republic of Korea.; Vellore Institute of Technology (VIT), Vellore, 632014, India., Hosseini V; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Dokmeci MR; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA., Ahadian S; Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA., Khademhosseini A; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA.; Department of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA.; Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.; Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
المصدر: Macromolecular bioscience [Macromol Biosci] 2023 Dec; Vol. 23 (12), pp. e2300276. Date of Electronic Publication: 2023 Aug 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101135941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1616-5195 (Electronic) Linking ISSN: 16165187 NLM ISO Abbreviation: Macromol Biosci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Weinheim, Germany : Wiley-VCH, c2001-
مواضيع طبية MeSH: Tissue Scaffolds*/chemistry , Bioprinting*, Insulin-Like Growth Factor I/pharmacology ; Tissue Engineering ; Muscle, Skeletal/physiology ; Muscle Fibers, Skeletal ; Hydrogels/pharmacology ; Hydrogels/chemistry ; Gelatin/pharmacology ; Gelatin/chemistry ; Printing, Three-Dimensional
مستخلص: Several microfabrication technologies have been used to engineer native-like skeletal muscle tissues. However, the successful development of muscle remains a significant challenge in the tissue engineering field. Muscle tissue engineering aims to combine muscle precursor cells aligned within a highly organized 3D structure and biological factors crucial to support cell differentiation and maturation into functional myotubes and myofibers. In this study, the use of 3D bioprinting is proposed for the fabrication of muscle tissues using gelatin methacryloyl (GelMA) incorporating sustained insulin-like growth factor-1 (IGF-1)-releasing microparticles and myoblast cells. This study hypothesizes that functional and mature myotubes will be obtained more efficiently using a bioink that can release IGF-1 sustainably for in vitro muscle engineering. Synthesized microfluidic-assisted polymeric microparticles demonstrate successful adsorption of IGF-1 and sustained release of IGF-1 at physiological pH for at least 21 days. Incorporating the IGF-1-releasing microparticles in the GelMA bioink assisted in promoting the alignment of myoblasts and differentiation into myotubes. Furthermore, the myotubes show spontaneous contraction in the muscle constructs bioprinted with IGF-1-releasing bioink. The proposed bioprinting strategy aims to improve the development of new therapies applied to the regeneration and maturation of muscle tissues.
(© 2023 Wiley-VCH GmbH.)
References: Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3287-92. (PMID: 19966309)
Exp Physiol. 2013 May;98(5):1038-52. (PMID: 23291913)
Sci Adv. 2016 May 27;2(5):e1600519. (PMID: 27386554)
Tissue Eng Part A. 2012 May;18(9-10):957-67. (PMID: 22115339)
Micromachines (Basel). 2019 Oct 09;10(10):. (PMID: 31601016)
J Biol Chem. 2007 Nov 30;282(48):35279-92. (PMID: 17916553)
Biomaterials. 2018 May;164:70-79. (PMID: 29499437)
Theranostics. 2021 Jan 1;11(1):48-63. (PMID: 33391460)
Front Physiol. 2020 Jul 24;11:811. (PMID: 32792975)
Science. 2017 Jun 9;356(6342):1035-1039. (PMID: 28596337)
Adv Healthc Mater. 2013 Apr;2(4):557-61. (PMID: 23184507)
Immunity. 2019 Jun 18;50(6):1482-1497.e7. (PMID: 31201094)
Chem Rev. 2017 Jun 28;117(12):7964-8040. (PMID: 28537383)
J Mater Sci Mater Med. 2008 Apr;19(4):1587-93. (PMID: 17992472)
Front Cardiovasc Med. 2018 Oct 23;5:147. (PMID: 30406114)
Nat Biotechnol. 2016 Mar;34(3):312-9. (PMID: 26878319)
Endocrinology. 2004 Nov;145(11):4803-5. (PMID: 15489312)
Int J Biol Macromol. 2021 Jul 31;183:918-926. (PMID: 33971227)
Biomaterials. 2015 Dec;73:254-71. (PMID: 26414409)
Curr Protoc Immunol. 2002 Aug;Chapter 21:Unit 21.4. (PMID: 18432882)
Biofabrication. 2023 Feb 03;15(2):. (PMID: 36689776)
Biomacromolecules. 2000 Spring;1(1):31-8. (PMID: 11709840)
Acta Biomater. 2015 Feb;13:101-10. (PMID: 25463489)
Small. 2019 Jun;15(24):e1805530. (PMID: 31012262)
Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-76. (PMID: 23614648)
Adv Healthc Mater. 2016 Jan 7;5(1):108-18. (PMID: 25880725)
Biomed Microdevices. 2004 Dec;6(4):279-87. (PMID: 15548875)
Sci Rep. 2018 Sep 17;8(1):13932. (PMID: 30224737)
J Microencapsul. 2019 May;36(3):267-277. (PMID: 31195912)
Biomaterials. 2017 Jul;131:98-110. (PMID: 28388499)
PLoS One. 2017 Feb 6;12(2):e0171417. (PMID: 28166248)
Adv Healthc Mater. 2016 Oct;5(20):2636-2645. (PMID: 27529631)
Sci Rep. 2020 Aug 6;10(1):13305. (PMID: 32764726)
World J Surg. 2001 Nov;25(11):1458-66. (PMID: 11760750)
Microsyst Nanoeng. 2017 Apr 24;3:16091. (PMID: 31057854)
Mol Biol Rep. 2020 Dec;47(12):9251-9258. (PMID: 33222041)
Pharm Dev Technol. 1998 May;3(2):269-76. (PMID: 9653765)
Adv Mater. 2016 Dec;28(48):10588-10612. (PMID: 27865007)
Exp Cell Res. 2018 Sep 1;370(1):168-173. (PMID: 29928867)
Biomaterials. 2007 Apr;28(13):2202-10. (PMID: 17267031)
Biomed Res Int. 2018 Apr 16;2018:1984879. (PMID: 29850487)
Trends Biotechnol. 2020 May;38(5):546-557. (PMID: 31954527)
Adv Drug Deliv Rev. 2012 Sep;64(12):1239-56. (PMID: 22433783)
J Biomater Sci Polym Ed. 2017 Nov;28(16):1826-1846. (PMID: 28696181)
Adv Healthc Mater. 2020 Jan;9(1):e1900626. (PMID: 31622051)
J Appl Physiol (1985). 2005 May;98(5):1900-8. (PMID: 15829723)
Biomaterials. 2019 Jun;206:160-169. (PMID: 30939408)
Biotechnol Bioeng. 2009 Feb 1;102(2):624-31. (PMID: 18958861)
Lab Chip. 2011 Feb 7;11(3):513-7. (PMID: 21116545)
PLoS One. 2020 May 6;15(5):e0232081. (PMID: 32374763)
Front Cell Dev Biol. 2022 Jul 11;10:952249. (PMID: 35898401)
Biomaterials. 2020 Jan;229:119584. (PMID: 31704468)
Tissue Eng Part B Rev. 2014 Oct;20(5):403-36. (PMID: 24320971)
Eur J Immunol. 1981 Oct;11(10):805-15. (PMID: 7308288)
Front Mol Biosci. 2021 Sep 22;8:677547. (PMID: 34631792)
Exp Biol Med (Maywood). 2014 Sep;239(9):1203-14. (PMID: 24912506)
معلومات مُعتمدة: R01 AR073135 United States AR NIAMS NIH HHS; AR073135 United States AR NIAMS NIH HHS; 1R01DK130566-01 United States DK NIDDK NIH HHS; AR073135 United States AR NIAMS NIH HHS; 1R01DK130566-01 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: 3D bioprinting; IGF-1; drug release; gelatin methacryloyl (GelMA); microfluidics; microparticle; muscle tissue engineering
المشرفين على المادة: 67763-96-6 (Insulin-Like Growth Factor I)
0 (Hydrogels)
9000-70-8 (Gelatin)
تواريخ الأحداث: Date Created: 20230803 Date Completed: 20231216 Latest Revision: 20240218
رمز التحديث: 20240218
مُعرف محوري في PubMed: PMC10837326
DOI: 10.1002/mabi.202300276
PMID: 37534566
قاعدة البيانات: MEDLINE
الوصف
تدمد:1616-5195
DOI:10.1002/mabi.202300276